Short-term Efficacy Of Sacubitril/Valsartan On Coronary Heart Disease-induced Heart Failure

Objective:The short-term clinical efficacy of sacubitril/valsartan and candesartan in patients with heart failure caused by coronary heart disease was evaluated,by observing the changes of cardiac function and other indicators between pre and post treatment.Methods:Fifty patients with chronic heart failure caused by coronary heart disease in Affiliated Nanhua Hospital from January 2019 to October 2019 were randomized.All enrolled patients were were randomly allocated in 1 : 1 fashion.Twenty-five patients in experimental group was to receive conventional anti-HF drugs and sacubitril/valsartan to replace ACEI/ARB,the else in control group was treated with conventional anti-HF drugs and candesartan(see below for specific administration methods).Comparing the index of the two groups of the data from echocardiography,the level of NT-proBNP,6 minute walk test and major adverse events after 3 months of treatment.Results:After three months of treatment,22(88%)of the 25 patients in the sacubitril/valsartan group completed the experiment,of which 2patients were lost to follow-up and 1 patient had hypotension.21(84%)of the 25 patients in the candesartan group completed the experiment,of which 1 patient had elevated serum creatinine,1 patient had hypotension and 2 patients were lost to follow-up.Data analysis as follows:(1)After three month treatment,either experimental group or control group,the level of LVEF,LVFS and 6 minute walk test were higher,and the level of NT-proBNP and heart rate were declined,with significantly statistical difference(p<0.05).(2)Compared with control group,the LVEF,LVFS and NT-proBNP of the sacubitril/valsartan group were significantly improved compared with the candesartan group after treatments,while the 6 minute walk test and heart rate with no significant difference.(3)There were no significant difference in changes of heart size after three month treatment between the two groups.(4)There were also no difference in the incidence of safety problems between the two groups.Conclusions:Sacubatril/valsartan can effectively improve cardiac function of patients with heart failure caused by coronary heart disease within 3 months.Within 3 months,these effects of sacurabatril/valsartan were more significant than candesartan,and did not increase the incidence of adverse reactions.